Navigation Links
YM BioSciences to raise approximately US$15 million
Date:3/5/2010

MISSISSAUGA, ON, March 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX:YM), today announced that it is raising approximately US$15 million in a "registered direct" offering of units at a price of US$1.20 per unit. Each unit consists of one common share and one half of one common share purchase warrant. Each whole warrant entitles the holder to acquire one common share at a price of US$1.60 commencing six months from closing for a period of five years from closing. Roth Capital Partners, LLC, served as lead placement agent. Bloom Burton & Co. Inc., Griffin Securities, Inc. and Haywood Securities Inc. served as co-placement agents for the transaction.

The funds will be used principally to fund YM's drug development activities and for general corporate purposes.

The transaction is expected to close on or about March 10, 2010, pending stock exchange approval.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the common shares in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development. Together with the products from YM Australia (formerly Cytopia Limited), the Company is currently developing four late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM); CYT 387, a JAK 1/2 small molecule inhibitor, CYT 997, a potent, vascular disrupting agent and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is importantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 9,000 patients reported as having been treated with nimotuzumab worldwide to date, Grade IV incidents of radiation dermatitis and incidents of severe rash have been only rarely observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been equally rare. Nimotuzumab is licensed to YM's majority-owned, Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. The products discovered by YM's recently acquired Australian subsidiary, YM Australia (formerly Cytopia Limited), include the JAK 1/2 inhibitor CYT387, and the novel VDA molecule CYT997. Both were discovered internally at Cytopia based on research led by Dr Andrew Wilks who identified the JAK 1/2 kinase enzymes. Both products are currently in clinical development. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF has met all endpoints in each of its trials including a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; that and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE YM BioSciences Inc.

Back to top
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
2. TEI Biosciences PriMatrix(TM) Awarded Seal of Approval by American Podiatric Medical Association
3. YM BioSciences presents CYT387 and CYT997 data at international cancer conference
4. YM BioSciences granted two US patents for AeroLEF(R)
5. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
6. YM BioSciences reports second quarter 2010 operational and financial results
7. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
8. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
9. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
10. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
11. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)...  On January 10 at the Medtech Showcase held ... Conference in San Francisco , ProclaRx ... to pharmaceutical leaders and public and private investors about ... and destroy biofilms.  Biofilms are a ... the body,s immune system from eradicating chronic infections. Infections with ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... the prestigious Tibbetts Award from the U.S. Small Business Administration. The ... created a significant economic or social impact […] and are considered the best of ...
(Date:1/14/2017)... -- The Alliance for Safe Biologic Medicines (ASBM) today issued ... guidance on biologic naming: We commend ... importance of distinct naming for all biologics, including biosimilars. ... will bring to patients, including new treatment options and ... the Guidance dealing with suffix design remains at odds ...
(Date:1/13/2017)... ... January 13, 2017 , ... Two Kalamazoo entrepreneurs have launched ... acid that farms, greenhouses and hydroponics operations use to increase yields and promote ... growing segments of customers using this high grade fulvic acid extracted from a ...
Breaking Biology Technology:
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a ... with the release of its patent-pending calibration device. With ... reliably perform calibrations, securely upload data logs and process ... the customer. "Fighting drunk driving through the ... the public at large, but also for the customer ...
(Date:1/6/2017)... 2017  Delta ID Inc., a leader in consumer-grade ... automotive at CES® 2017. Delta ID has collaborated with ... the use of iris scanning as a secure, reliable ... in a car, and as a way to elevate ... Delta ID and Gentex will demonstrate (booth #7326 ...
(Date:12/22/2016)... Dec. 20, 2016  As part of its longstanding mission ... personal genetics company, recently released its latest children,s book, titled ... book focuses on the topics of inheritance and variation of ... (NGSS) taught in elementary school classrooms in the US. ... by illustrator Ariana Killoran , whose previous book with ...
Breaking Biology News(10 mins):